{"id":31589,"date":"2022-10-19T09:54:23","date_gmt":"2022-10-19T07:54:23","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=31589"},"modified":"2022-10-25T08:17:56","modified_gmt":"2022-10-25T06:17:56","slug":"leserbrief-behandlung-von-long-covid-und-post-covid-syndrom","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2022\/leserbrief-behandlung-von-long-covid-und-post-covid-syndrom","title":{"rendered":"Leserbrief: Behandlung von Long COVID- und Post-COVID-Syndrom"},"content":{"rendered":"<p>Frage von Dr. P. aus S.: &gt;&gt; Ich bin Hausarzt und momentan viel mit (Post-)COVID konfrontiert. Was kann evidenzbasiert gesagt werden \u00fcber die Wirksamkeit von Mastzell-Stabilisatoren und Vitamin\u00a0C bei Post-COVID-Zust\u00e4nden und was zu Ivabradin beim posturalen Tachykardie-Syndrom (POTS)? Dies wird in patientengef\u00fchrten Selbsthilfegruppen momentan hei\u00df diskutiert, bei Kollegen und Kolleginnen aber nicht. &lt;&lt; Antwort: &gt;&gt; [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Frage von Dr. P. aus S.: &gt;&gt; Ich bin Hausarzt und momentan viel mit (Post-)COVID konfrontiert. Was kann evidenzbasiert gesagt werden \u00fcber die Wirksamkeit von Mastzell-Stabilisatoren und Vitamin\u00a0C bei Post-COVID-Zust\u00e4nden und was zu Ivabradin beim posturalen Tachykardie-Syndrom (POTS)? Dies wird in patientengef\u00fchrten Selbsthilfegruppen momentan hei\u00df diskutiert, bei Kollegen und Kolleginnen aber nicht. &lt;&lt; Antwort: &gt;&gt; [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5340,5339,5753,5754,5338],"class_list":["post-31589","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-coronavirus","tag-covid-19","tag-long-covid","tag-post-covid","tag-sars-cov-2"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/31589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=31589"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/31589\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=31589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=31589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=31589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}